Biocytogen Pharms (Beijing)2315
Mentioned
As of the close on July 17, the CRO concept sector fell 8.83% overall, ranking among the top decliners. Within the sector, Bio-Key hit the 20% daily limit down, while Asymchem, Lingkang Pharmaceutical, and Baihua Pharmaceutical also hit limit down. BioMap, Haoyuan Chemexpress, and Hongbo Pharmaceutical led the declines. In terms of capital flows, the sector saw a net outflow of 3.421 billion yuan in main funds for the day, with 63 stocks experiencing net outflows and seven stocks seeing net outflows exceeding 100 million yuan. The largest outflow was from WuXi AppTec, reaching 944 million yuan, followed by Pharmaron, HitGen, and Zhaoyan New Drug with net outflows of 378 million yuan, 173 million yuan, and 154 million yuan respectively.
Biocytogen Pharms (Beijing)
Shenzhen Hepalink Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Co Ltd
Asymchem Laboratories Tian Jin Co Ltd
Aba Chemicals Corp
Zhejiang Canaan Technology Co Ltd
Wuhan Hiteck Biological Pharma Co Ltd
Hunan Jiudian Pharmaceutical Co Ltd
Pharmaron Beijing Co Ltd
Pony Testing International Group Co
Inno Laser Technology Co. Ltd.
Shanghai Labway Clinical Laboratory Co Ltd
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
MeHow Innovative Ltd. A
Xinjiang Baihuacun Co Ltd
Joinn Laboratories(China)Co
Zhejiang Ausun Pharmaceutical Co Ltd
WuXi AppTec Co Ltd
Great-Sun Foods Co Ltd
Lionco Pharm Grp Co Ltd
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Nanjing Vazyme Biotech Co Ltd
Shanghai Haoyuan Chemexpress Co. Ltd. A
Suzhou Novoprotein Scientific Co. Ltd. A
Cansino Biologics Inc
HitGen Inc. A
Sinocelltech Group Ltd